Page 3 - Seog Kim News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Baden wübergNew yorkUnited statesSoult ukpyolsiSouth koreaSeog kimAlex fudukidisAdi hoessAlexander fudukidisdirectorContactmary beth sandinUniversity of texas md anderson cancer centerOncology at samsung medical centerWall streetChief executive officerWon seog kimSamsung medical center

Affimed Reports Topline Data from AFM13 Monotherapy Phase 2 REDIRECT Study in Patients with Relapsed or Refractory Peripheral T Cell Lymphoma

Baden wübergNew yorkUnited statesSoult ukpyolsiSouth koreaSeog kimAlex fudukidisAdi hoessMary beth sandinAlexander fudukidisUniversity of texas md anderson cancer centerOncology at samsung medical centerChief executive officerWon seog kimSamsung medical centerCancer center

Sorrento Announces Positive Phase II Results of PD-L1

IMC-001, a PD-L1 monoclonal antibody selected from Sorrento’s G-MAB library, demonstrated impressive therapeutic effects in patients with heavily treated.

South koreaSeog kimBrian cooleyHenry jiImmuneoncia seongnamSemnur pharmaceuticals incAsian congressExchange commissionSorrento therapeutics incSamsung medical centerImmuneoncia therapeuticsPivotal trialc le ar programScilex pharmaceuticals incEuropean society for medical oncologyYuhan corporation of koreaYuhan corporation

Sorrento Therapeutics (SRNE) Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology

Sorrento Therapeutics (SRNE) Announces Positive Phase II Results of PD-L1 Checkpoint Inhibitor IMC-001 Presented at Asian Congress of the European Society for Medical Oncology
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

South koreaSeog kimHenry jiImmuneoncia seongnamSorrento therapeutics incSamsung medical centerImmuneoncia therapeuticsAsian congressYuhan corporation of koreaEuropean society for medical oncologyYuhan corporationEuropean societyMedical oncologyWon seog kimPrincipal investigatorTae kim

Dizal Announces New Data from the Phase I/II Study of Golidocitnib in Refractory or Relapsed Peripheral T Cell Lymphoma Selected for Oral Presentation at 2022 EHA Annual Meeting

/PRNewswire/ Dizal (SSE: 688192) will present the data from an ongoing phase I/II study of golidocitnib, a selective JAK1 inhibitor, in refractory or.

Seog kimXiaolin zhangInternational conference on malignant lymphomaSamsung medical centerEuropean hematology associationBusiness developmentHybrid congressTrack designationMalignant lymphomaChief executive officerFast trackAggressive lymphomaAbstract codeWon seog kimSamsung medicalDizal pharmaceutical